Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
Treprostinil
Medication labelOrenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve…
Why this: Advisory · dailymed-prescription
Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).
- generic_name
- treprostinil
- product_names
- treprostinil
- ndc
- 66302-300, 66302-302, 66302-310, 66302-325, 66302-350, 66302-361, 66302-362, 66302-363, 66302-300-01, 66302-300-10, 66302-300-02, 66302-302-01, 66302-302-10, 66302-302-02, 66302-310-01, 66302-310-10, 66302-310-02, 66302-325-01, 66302-325-10, 66302-325-02, 66302-350-01, 66302-350-10, 66302-350-02, 66302-361-28, 66302-362-56, 66302-363-84
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en